What Is Bio-Remodelling and How Does Profhilo Work?
The term bio-remodelling refers to a category of injectable treatments designed not to add volume in a localised area, but to stimulate the skin's own regenerative processes. Rather than filling a specific contour, a bio-remodelling product interacts with the surrounding tissue to encourage the production of collagen, elastin and other structural proteins that decline with age.
Profhilo, manufactured by IBSA Derma, is the most widely recognised bio-remodelling product available in the UK aesthetics market. Its composition is central to understanding how it works. Profhilo contains a very high concentration of hyaluronic acid (64 mg per 2 ml) formed through a patented thermal bonding process called NAHYCO Technology. This process combines high molecular weight and low molecular weight hyaluronic acid without the use of chemical cross-linking agents. The absence of cross-linking is significant: it means the product is not designed to hold a structural shape, but instead disperses through multiple tissue planes after injection.
Once distributed, the hyaluronic acid interacts with receptors on keratinocytes, fibroblasts and adipocyte stem cells. The manufacturer Summary of Product Characteristics describes this as stimulating the synthesis of collagen types I, III and IV as well as elastin. The clinical result is an improvement in skin tone, hydration, firmness and laxity rather than a change in facial contour. This is what distinguishes bio-remodelling conceptually from conventional augmentation.
The standard Profhilo protocol involves two treatment sessions spaced four weeks apart. The bio-distribution of the product means that a small number of anatomically defined injection points are sufficient to achieve widespread tissue coverage. This is described in detail in the manufacturer's clinical training materials and product literature.
How Conventional Hyaluronic Acid Dermal Fillers Differ
Conventional dermal fillers also use hyaluronic acid as their primary component, but the manufacturing process and clinical intention are fundamentally different. The hyaluronic acid in a dermal filler is chemically cross-linked, most commonly using a compound called BDDE (butanediol diglycidyl ether) in varying concentrations. Cross-linking creates a cohesive gel that resists enzymatic breakdown and retains its shape within the tissue.
Different filler formulations are engineered to produce different rheological properties. A highly cohesive, dense gel is suited to deep structural volumisation, such as cheek augmentation or chin projection. A softer, more pliable gel is better suited to fine lines or delicate areas such as the lips and tear troughs. Manufacturers express these properties through parameters including G-prime (elastic modulus, reflecting firmness) and cohesivity. Practitioners selecting products for specific indications should review the manufacturer SPC and published rheological data for each product.
The intended clinical outcome of a conventional filler is therefore quite specific: to place a defined volume of material in a defined anatomical location. The result is visible immediately after treatment, with the filler occupying space beneath the skin to restore or create structure. This is a physical rather than a biological effect, which is why the mechanism is so different from that of a bio-remodelling product.
It is also worth noting that hyaluronic acid dermal fillers are reversible: they can be partially or fully dissolved using hyaluronidase enzyme. This is an important safety consideration and is covered in guidance published by the Joint Council for Cosmetic Practitioners (JCCP) and training bodies operating under the UK's non-surgical aesthetics framework.
Expected Clinical Duration and Managing Patient Expectations
One of the most common points of confusion for patients relates to duration of effect, because profhilo duration and the longevity of conventional fillers operate on different principles.
For Profhilo, the bio-remodelling effect is a biological response: the stimulation of new collagen and elastin synthesis. The manufacturer Summary of Product Characteristics notes that visible improvements in skin quality are typically observed at four weeks after the second session and are generally maintained for around six months. Because the mechanism is biological rather than physical, maintenance sessions are typically advised at six-monthly intervals to sustain the result.
For conventional hyaluronic acid dermal fillers, duration depends on the specific product, the area treated, the patient's metabolism, and the volume injected. Published clinical data across major licensed filler ranges indicates a broad spectrum: lighter products in superficial lines may last six to nine months, while denser volumising products can persist for twelve months or longer. Some patients in clinical studies have maintained results for up to eighteen months in areas of low muscular activity. Practitioners should refer to the specific SPC for each product rather than applying a general duration figure.
Clear communication about the nature of the result is important for both product categories. Patients should understand that Profhilo improves skin quality rather than changing their features, and that filler results are structural rather than regenerative. Conflating the two leads to unmet expectations.
Practitioner Buying Considerations
From a treatment-planning and stock perspective, Profhilo and conventional dermal fillers serve different patient cohorts, though there is significant overlap.
Patient demand for bio-remodelling has grown substantially in the UK over the past five years, driven in part by increased patient literacy about skin ageing mechanisms beyond volume loss. Patients who are concerned about skin laxity, dullness, fine texture changes or generalised lack of firmness are often good candidates for a bio-remodelling conversation, even if they initially present asking about fillers. This creates an opportunity to broaden the treatment discussion.
Conversely, patients seeking structural correction (loss of cheek projection, nasolabial depth, lip definition) require a conventional filler formulation. Attempting to address these concerns with a bio-remodelling product alone is unlikely to meet clinical goals, because the product does not provide physical volume support.
Practitioners should also consider the storage, shelf-life and licensing requirements for each product category. All prescription-only aesthetics products dispensed in the UK must be supplied under a valid prescription from a registered prescriber, in accordance with the Human Medicines Regulations 2012. Sourcing from a licensed wholesale dealer operating under a Wholesale Dealer's Authorisation (WDA) issued by the Medicines and Healthcare products Regulatory Agency (MHRA) is a regulatory requirement, not a preference.
How the Two Can Work Together
The most clinically coherent approach for many patients is to use dermal fillers and a hyaluronic acid skin booster such as Profhilo as complementary rather than competing treatments.
A structured protocol might address structural volume first, using an appropriate filler to restore the mid-face, support the jawline or refine the lips, and then introduce Profhilo in a separate session to address the overlying skin quality. In this sequence, fillers provide the architectural foundation and Profhilo addresses the biological quality of the skin itself: its hydration, elasticity and firmness.
Some practitioners prefer to begin with bio-remodelling, particularly in younger patients where volume loss is not yet significant but early skin laxity is beginning to appear. In these cases, Profhilo may address the presenting concern without any need for structural filler. The decision depends on a full clinical assessment and should not be protocol-driven in isolation from patient anatomy and goals.
There is published observational data, referenced in IBSA Derma's clinical literature, supporting the combined use of bio-remodelling and conventional fillers. Practitioners interested in the evidence base are encouraged to review the peer-reviewed studies cited in the manufacturer's product dossier and to engage with continuing professional development programmes offered by recognised aesthetics training bodies in the UK.
In summary, understanding the distinction between profhilo vs dermal fillers is not a matter of choosing one over the other. It is a matter of understanding what each product can and cannot do, and deploying each appropriately within a considered, patient-centred treatment plan.
Frequently Asked Questions
What is the difference between Profhilo and a dermal filler?
Profhilo is a bio-remodelling injectable containing ultra-pure, thermally bonded high and low molecular weight hyaluronic acid. It spreads through tissue to stimulate collagen and elastin rather than adding volume in a localised area. Conventional dermal fillers use cross-linked hyaluronic acid to resist degradation and hold a defined shape, making them suited to volumisation and contouring. The two products serve distinct clinical purposes.
How long does Profhilo last compared to dermal fillers?
Clinical data cited in the manufacturer Summary of Product Characteristics indicates that the tissue-remodelling effects of Profhilo are typically maintained for around six months following the standard two-session protocol. Cross-linked dermal fillers vary considerably: lighter products used in fine lines may last six to nine months, while denser volumising fillers can persist for twelve months or longer according to individual manufacturer SPCs.
Can Profhilo and dermal fillers be used at the same time?
Yes. Many practitioners treat with dermal fillers first to restore structural volume, then introduce Profhilo to address skin quality, laxity and hydration. The two approaches are complementary rather than competing. The sequencing and interval between treatments should be determined by the treating practitioner based on individual patient assessment.
Is Profhilo suitable for all skin types?
Profhilo is generally well tolerated across skin types. As with any injectable product, contraindications listed in the manufacturer Summary of Product Characteristics must be reviewed, including hypersensitivity to hyaluronic acid preparations. A thorough medical and allergy history is essential before treatment.
What patient demand is there for bio-remodelling treatments in the UK?
Interest in bio-remodelling and skin quality treatments has grown significantly in the UK aesthetics sector over recent years, driven partly by increased patient awareness of skin laxity concerns beyond volumisation. Practitioners report that patients who have previously received dermal fillers often enquire about complementary skin-quality options, making bio-remodelling a natural addition to a treatment menu.